U.S.‑based Definium Therapeutics is developing DT120, a medical low‑dose form of lysergide (LSD), as a potential oral treatment for several psychiatric conditions. In June, the company announced phase III data showing that the treatment significantly reduces symptoms of severe depression. Now the company is presenting another success, this time in generalized anxiety disorder (GAD).
Phase III win for LSD‑based anxiety drug
An LSD‑based drug candidate for anxiety disorders is reported to show strong results in late‑stage clinical testing.
Advertisement
BREAKING